|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Alvine Pharmaceuticals Inc. |
|---|---|
| Information provided by: | Alvine Pharmaceuticals Inc. |
| ClinicalTrials.gov Identifier: | NCT00669825 |
Purpose
ALV003-0812 is a study of the safety and tolerability of a study drug (ALV003) in healthy adult volunteers and in patients with well-controlled celiac disease, following a meal that contains gluten.
| Condition | Intervention | Phase |
|---|---|---|
|
Celiac Disease |
Drug: ALV003 Drug: Placebo |
Phase I |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Crossover Assignment Masking: Single Blind (Subject) Primary Purpose: Basic Science |
| Official Title: | A Phase 1, Two Stage, Single-Blind, Single Dose, Placebo Controlled, Dose Escalation, Crossover Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal |
| Estimated Enrollment: | 36 |
| Study Start Date: | March 2008 |
| Study Completion Date: | October 2008 |
| Primary Completion Date: | October 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: A
Placebo
|
Drug: Placebo
Placebo to be administered via intragastric tube
|
|
Active Comparator: B
ALV003 (Active Study Drug)
|
Drug: ALV003
Doses via intragastric tube at dosages of either 100 mg, 300 mg, 900 mg, or 1800 mg
|
ALV003-0812 (the FED study) is designed to evaluate the safety and tolerability of a single dose of the study drug, ALV003, administered at one of four different dose levels, and following a test meal containing a small amount (1 gram) of gluten. ALV003 has been demonstrated to proteolyze (assist with the digestion of) various forms of gluten (gluten flour, wheat bread) in laboratory studies and in animals. Celiac disease has been estimated to affect 1% of the population of the United States, is related to gluten, and has a wide range of clinical manifestations including chronic gastrointestinal symptoms, malabsorption, and bone disease.
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Subjects with well-controlled celiac disease (CD), in good health with the exception of CD
Exclusion Criteria:
Clinically significant abnormal lab values, as determined by the PI
Medical history (Healthy volunteers)
Medical History (well-controlled CD subjects)
Contacts and Locations| United States, California | |
| Clinical Applications Laboratories, Inc. | |
| San Diego, California, United States, 92103 | |
| Clinical Applications Laboratories | |
| San Diego, California, United States, 92103 | |
| Principal Investigator: | Vijaya Pratha, MD | Clinical Applications Laboratories |
More Information
| Responsible Party: | Vijaya Pratha, MD, Principal Investigator, Clinical Applications Laboratories Inc. |
| ClinicalTrials.gov Identifier: | NCT00669825 History of Changes |
| Other Study ID Numbers: | ALV003-0812 |
| Study First Received: | April 21, 2008 |
| Last Updated: | February 17, 2010 |
| Health Authority: | United States: Food and Drug Administration |
|
Celiac Disease |
|
Celiac Disease Malabsorption Syndromes Intestinal Diseases |
Gastrointestinal Diseases Digestive System Diseases Metabolic Diseases |